Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP331792.RAqZmqEwwbifAygmrkK1_2V-Eq5yJ0xna-LjAJHuPrFq0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP331792.RAqZmqEwwbifAygmrkK1_2V-Eq5yJ0xna-LjAJHuPrFq0130_assertion type Assertion NP331792.RAqZmqEwwbifAygmrkK1_2V-Eq5yJ0xna-LjAJHuPrFq0130_head.
- NP331792.RAqZmqEwwbifAygmrkK1_2V-Eq5yJ0xna-LjAJHuPrFq0130_assertion description "[However, recent reports of myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) developing after treatment with immunosuppressants and G-CSF has raised concern over the use of this agent in patients with aplastic anemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP331792.RAqZmqEwwbifAygmrkK1_2V-Eq5yJ0xna-LjAJHuPrFq0130_provenance.
- NP331792.RAqZmqEwwbifAygmrkK1_2V-Eq5yJ0xna-LjAJHuPrFq0130_assertion evidence source_evidence_literature NP331792.RAqZmqEwwbifAygmrkK1_2V-Eq5yJ0xna-LjAJHuPrFq0130_provenance.
- NP331792.RAqZmqEwwbifAygmrkK1_2V-Eq5yJ0xna-LjAJHuPrFq0130_assertion SIO_000772 14607763 NP331792.RAqZmqEwwbifAygmrkK1_2V-Eq5yJ0xna-LjAJHuPrFq0130_provenance.
- NP331792.RAqZmqEwwbifAygmrkK1_2V-Eq5yJ0xna-LjAJHuPrFq0130_assertion wasDerivedFrom befree-20150227 NP331792.RAqZmqEwwbifAygmrkK1_2V-Eq5yJ0xna-LjAJHuPrFq0130_provenance.
- NP331792.RAqZmqEwwbifAygmrkK1_2V-Eq5yJ0xna-LjAJHuPrFq0130_assertion wasGeneratedBy ECO_0000203 NP331792.RAqZmqEwwbifAygmrkK1_2V-Eq5yJ0xna-LjAJHuPrFq0130_provenance.